Journal
TRENDS IN MOLECULAR MEDICINE
Volume 28, Issue 4, Pages 290-303Publisher
CELL PRESS
DOI: 10.1016/j.molmed.2022.02.001
Keywords
-
Funding
- National Institutes of Health NIDDK [RO1DK104344-01A1]
Ask authors/readers for more resources
Postbiotics, critical effectors of probiotics' activity, have shown potential as therapeutics for treating fragile patients. This article discusses recent studies on probiotics and postbiotics, highlighting the use of organoids and nontransformed preclinical models to understand the impact of microbial communities on gut health. The authors also offer their perspective on future directions in this field.
Postbiotics have recently emerged as critical effectors of the activity of probiotics and, because of their safety profile, they are considered potential therapeutics for the treatment of fragile patients. Here, we present recent studies on probiotics and postbiotics in the context of novel discovery tools, such as organoids and organoid-based platforms, and nontransformed preclinical models, that can be generated from intestinal stem cells. The implementation of organoid-related techniques is the next gold standard for unraveling the effect of microbial communities on homeostasis, inflammation, idiopathic diseases, and cancer in the gut. We also summarize recent studies on biotics in organoid-based models and offer our perspective on future directions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available